Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models

Project: Research project

Project Details

Description

Project Summary/Abstract Oropharyngeal squamous cell carcinoma (OPSCC) has emerged as a significant global health concern, with increasing incidence attributed to human papillomavirus (HPV) infection. Additionally, individuals living with HIV/AIDS (PLWH) face a higher risk of developing OPSCC. Understanding the synergistic relationships between HIV and oral HPV infection in OPSCC development is critical for advancing prevention, diagnosis, and treatment strategies. CD8+ T cells play a pivotal role in antiviral immunity and tumor surveillance. However, the impact of HIV infection on CD8+ T cells remains largely unexplored. Recently, we have identified an HPV integration hotspot in the PD-L1 gene, contributing to CD8+ T cell exhaustion. In addition, our single-cell analysis revealed a unique subset of exhausted CD8+ T cells associated with HIV-HPV co-infection in the OPSCC microenvironment. We hypothesize that HIV co-infection induces elevated dysfunction/exhaustion of tumor- infiltrating lymphocytes (TILs), particularly CD8+ T cells, in the OPSCC microenvironment. As a multi-PI application, combining our expertise in single-cell analysis and functional analysis of HIV mouse models and CD8+ T cells, we will investigate the impact of HIV infection on the immune cell landscape of HPV-positive OPSCC (Aim 1). Additionally, we will characterize the phenotype and specificity of tumor-infiltrating CD8+ T cell receptors (TCRs) and correlate them with cellular exhaustion status in the context HIV-HPV co-infection (Aim 2). Furthermore, we will establish a novel mouse model that faithfully recapitulates HIV-HPV co-infection in OPSCC to explore dynamic interactions between viral infection, tumor progression, and CD8+ T cells (Aim 3). Additionally, we will investigate the impact of combined antiretroviral therapy (ART) and immune checkpoint blockade on restoring tumor-reactive CD8+ T cell function and preventing HPV-induced neoplastic growth. This research aims to enhance our understanding of HIV-HPV co-infection's influence on immune responses and immune evasion in oropharyngeal cancer. Findings may inform novel therapeutic strategies to enhance immune responses and improve clinical outcomes for OPSCC patients living with HIV and have broader implications for other HPV-associated malignancies.
StatusActive
Effective start/end date6/1/245/31/26

Funding

  • National Cancer Institute: $578,249.00
  • National Cancer Institute: $578,249.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.